Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Companies announce presentation of PXD101 phase I results at ASCO
June 16th, 2005
CuraGen Corp. (CRGN) and TopoTarget, A/S, announced that preliminary phase I data on PXD101, a small-molecule histone deacetylase (HDAC) inhibitor for the treatment of advanced solid tumors, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida. This phase I, open-label study was designed to determine the safety, maximum-tolerated dose, pharmacokinetics, and pharmacodynamics of intravenously administered PXD101, as well as initial assessment of the pharmacokinetics of orally administered PXD101. PXD101 was administered as a single agent to patients with advanced solid tumors whose disease was refractory to standard therapy...
Source: Women's Health Weekly (2005-06-16)
|
